Work

5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC

Year: 2025

Type: article

Study design: Observational Study

Source: Immunotherapy

DOI: 10.1080/1750743x.2025.2569856

Authors: Stephen V. Liu, Riddhi A. Babel, Yu-Han Kao, Diana Chirovsky, Azadeh Namakydoust, Vamsidhar Velcheti

Institutions: Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, Merck & Co., Inc., Rahway, NJ, USA (United States), NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4415300809

FWCI: 1.215

Cites: 33

Cited by: 2

Related to: